CSIMarket
 


Applied Genetic Technologies Corporation  (AGTC)
Other Ticker:  
 
 

AGTC's Capital Expenditures Growth by Quarter and Year

Applied Genetic Technologies's Capital Expenditures results by quarter and year




AGTC Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter June - 0.86 0.51 0.04
III Quarter March - 0.20 0.37 0.47
II Quarter December - 0.34 0.22 0.33
I Quarter September 0.30 0.62 0.76 0.36
FY   0.30 2.02 1.86 1.20



AGTC Capital Expenditures first quarter 2023 Y/Y Growth Comment
Applied Genetic Technologies Corporation reported drop in Capital Expenditures in the first quarter 2023 by -50.97% to $ 0.30 millions, from the same quarter in 2022.
The fall in the first quarter 2023 Applied Genetic Technologies Corporation's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 124.13%.

Looking into first quarter 2023 results within Biotechnology & Pharmaceuticals industry 81 other companies have achieved higher Capital Expenditures growth. While Applied Genetic Technologies Corporation' s Capital Expenditures meltdown of -50.97% ranks overall at the positon no. 1913 in the first quarter 2023.




AGTC Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter June - 68.63 % 1175 % -50 %
III Quarter March - -45.95 % -21.28 % 487.5 %
II Quarter December - 54.55 % -33.33 % 266.67 %
I Quarter September -50.97 % -18.42 % 111.11 % 500 %
FY   - 8.6 % 55 % 287.1 %

Financial Statements
Applied Genetic Technologies's first quarter 2023 Capital Expenditures $ 0.30 millions AGTC's Income Statement
Applied Genetic Technologies's first quarter 2022 Capital Expenditures $ 0.62 millions Quarterly AGTC's Income Statement
New: More AGTC's historic Capital Expenditures Growth >>


AGTC Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter June - 330 % 37.84 % -91.49 %
III Quarter March - -41.18 % 68.18 % 42.42 %
II Quarter December - -45.16 % -71.05 % -8.33 %
I Quarter September -64.65 % 21.57 % 1800 % 350 %
FY (Year on Year)   - 8.6 % 55 % 287.1 %




Capital Expenditures first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #82
Healthcare Sector #298
Overall #1913

Capital Expenditures Y/Y Growth Statistics
High Average Low
1003.25 % 124.13 % -87.89 %
(Dec 31 2016)   (Dec 31 2017)
Capital Expenditures first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #82
Healthcare Sector #298
Overall #1913
Capital Expenditures Y/Y Growth Statistics
High Average Low
1003.25 % 124.13 % -87.89 %
(Dec 31 2016)   (Dec 31 2017)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Applied Genetic Technologies's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
12900 % 556.99 % -96.92 %
(Mar 31 2018)  


AGTC's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2023 Applied Genetic Technologies Corporation realized fall in Capital Expenditures sequentially by -64.65% to $ 0.30 millions, from $ 0.86 millions achived in the previous quarter.

Even periodic factors were not able to recover the I. Quarter for the Applied Genetic Technologies Corporation, Kayla P. Walsh, Healthcare sector researcher pointed out, she mentioned certan caution for the AGTC's direction.

Within Biotechnology & Pharmaceuticals industry 105 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Applied Genetic Technologies's Capital Expenditures growth quarter on quarter, overall rank is 2824.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #106
Healthcare Sector #552
Overall #2824
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #106
Healthcare Sector #552
Overall #2824
Capital Expenditures Q/Q Growth Statistics
High Average Low
12900 % 556.99 % -96.92 %
(Mar 31 2018)  


AGTC's I. Quarter Q/Q Capital Expenditures Comment
In the I. Quarter 2023 Applied Genetic Technologies Corporation disclosed fall in Capital Expenditures from the previous quarter by -64.65% to $ 0.30 millions, from $ 0.86 millions achived a quarter before.

Albeit periodic influence commonly energize I. Quarter 2023 Capital Expenditures, that clearly could not be substantial to rescue AGTC's I. Quarter performance, Kayla P. Walsh, Healthcare sector researcher said and continued that average quarter on quarter Capital Expenditures growth is at 556.99% for AGTC.

Within Biotechnology & Pharmaceuticals industry 105 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Applied Genetic Technologies's Capital Expenditures growth quarter on quarter, overall rank is 2824.


Applied Genetic Technologies's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Capital Expenditures 12 Months Ending $ 1.70 $ 2.01 $ 1.67 $ 1.83 $ 1.72
Y / Y Capital Expenditures Growth (TTM) -0.76 % 8.22 % 20.13 % 23.2 % 7.59 %
Year on Year Capital Expenditures Growth Overall Ranking # 1631 # 1881 # 1650 # 564 # 1168
Seqeuential Capital Expenditures Change (TTM) -15.44 % 20.96 % -9.12 % 6.76 % -7.79 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1913 # 792 # 2736 # 648 # 1144




Cumulative Capital Expenditures growth Comment
For the 12 months ended Sep 30 2022 Applied Genetic Technologies reported a decrease in Capital Expenditures by -0.76% year on year, to $2 millions, compare to the 8.22% growth at Jun 30 2022.

In the Healthcare sector 249 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1631, from total ranking in previous quarter at 1881.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1003.25 %
124.13 %
-87.89 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 82
Healthcare Sector # 250
Overall # 1631

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1003.25 %
124.13 %
-87.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 82
Sector # 298
S&P 500 # 1913
Cumulative Capital Expenditures growth Comment
For the 12 months ended Sep 30 2022 Applied Genetic Technologies reported a decrease in Capital Expenditures by -0.76% year on year, to $2 millions, compare to the 8.22% growth at Jun 30 2022.

In the Healthcare sector 249 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1631, from total ranking in previous quarter at 1881.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
1003.25 %
124.13 %
-87.89 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 82
Healthcare Sector # 250
Overall # 1631

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
1003.25 %
124.13 %
-87.89 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 82
Sector # 298
S&P 500 # 1913




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
AGTC's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for AGTC's Competitors
Capital Expenditures Growth for Applied Genetic Technologies's Suppliers
Capital Expenditures Growth for AGTC's Customers

You may also want to know
AGTC's Annual Growth Rates AGTC's Profitability Ratios AGTC's Asset Turnover Ratio AGTC's Dividend Growth
AGTC's Roe AGTC's Valuation Ratios AGTC's Financial Strength Ratios AGTC's Dividend Payout Ratio
AGTC's Roa AGTC's Inventory Turnover Ratio AGTC's Growth Rates AGTC's Dividend Comparisons



Companies with similar Capital Expenditures decrease for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2022
Tela Bio Inc -0.34%$ -0.344 millions
Edwards Lifesciences Corporation-1.32%$ -1.318 millions
Neuroone Medical Technologies Corporation-1.34%$ -1.337 millions
Guardant Health Inc -1.91%$ -1.910 millions
Seagen Inc -2.56%$ -2.556 millions
Addus Homecare Corporation-3.00%$ -2.999 millions
Concert Pharmaceuticals Inc -3.03%$ -3.030 millions
Merck and Co Inc -3.92%$ -3.925 millions
Precision Optics Corporation Inc -3.93%$ -3.925 millions
Nextcure Inc -4.32%$ -4.317 millions
Electromed Inc -5.19%$ -5.185 millions
Sight Sciences Inc -5.23%$ -5.226 millions
Veracyte inc -5.41%$ -5.408 millions
Baxter International Inc -6.15%$ -6.145 millions
Natera inc -7.06%$ -7.057 millions
Sio Gene Therapies Inc -7.14%$ -7.143 millions
Replimune Group Inc -7.48%$ -7.477 millions
Rockwell Medical inc -7.87%$ -7.874 millions
Harvard Bioscience Inc-7.92%$ -7.917 millions
Bristol myers Squibb Company-8.52%$ -8.519 millions
Davita Inc -8.54%$ -8.535 millions
Dentsply Sirona Inc -8.57%$ -8.571 millions
Sunlink Health Systems Inc -9.83%$ -9.827 millions
Moderna Inc -10.10%$ -10.101 millions
Rhythm Pharmaceuticals inc -10.38%$ -10.377 millions
Sarepta Therapeutics Inc -10.93%$ -10.930 millions
West Pharmaceutical Services Inc -11.49%$ -11.485 millions
Recursion Pharmaceuticals Inc -11.78%$ -11.776 millions
Cytek Biosciences Inc -12.08%$ -12.080 millions
Universal Health Services Inc -12.09%$ -12.089 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com